New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma by Byrne, Katelyn T & Turk, Mary Jo
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
9-10-2011
New Perspectives on the Role of Vitiligo in
Immune Responses to Melanoma
Katelyn T. Byrne
Dartmouth College
Mary Jo Turk
Dartmouth College
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Immunology and Infectious Disease Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Byrne, Katelyn T. and Turk, Mary Jo, "New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma" (2011). Open
Dartmouth: Faculty Open Access Articles. 3878.
https://digitalcommons.dartmouth.edu/facoa/3878
www.impactjournals.com/oncotarget/ Oncotarget, September, Vol.2, No 9
Oncotarget 2011; 2:  684 - 694www.impactjournals.com/oncotarget 684
New Perspectives on the Role of Vitiligo in Immune Responses 
to Melanoma
Katelyn T. Byrne and Mary Jo Turk
1 Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH, USA
Correspondence to: Mary Jo Turk, email: mary.jo.turk@dartmouth.edu
Keywords: melanoma, vitiligo, melanocytes, CD8 T cells, CD4 T cells, T cell memory
Received: September 7, 2011, Accepted: September 9, 2011, Published: September 10, 2011
Copyright: © Byrne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Melanoma-associated vitiligo is the best-studied example of the linkage between 
tumor immunity and autoimmunity. Although vitiligo is an independent positive 
prognostic factor for melanoma patients, the autoimmune destruction of melanocytes 
was long thought to be merely a side effect of robust anti-tumor immunity. However, 
new data reveal a key role for vitiligo in supporting T cell responses to melanoma. This 
research perspective reviews the history of melanoma-associated vitiligo in patients, 
the experimental studies that form the basis for understanding this relationship, 
and the unique characteristics of melanoma-specific CD8 T cells found in hosts with 
vitiligo. We also discuss the implications of our recent findings for the interpretation 
of patient responses, and the design of next-generation cancer immunotherapies.
INTRODUCTION
The past several decades of research in tumor 
immunology have revealed a strong link between 
tumor immunity and autoimmunity. This connection is 
first understood in the context of the extensive overlap 
between antigens expressed by a tumor and its normal 
tissue counterpart [1, 2]. The best-studied example of 
concurrent tumor immunity and autoimmunity is the 
development of vitiligo in association with melanoma. 
Vitiligo, or the autoimmune destruction of melanocytes, 
is an independent positive prognostic factor for melanoma 
patients [3-5], and its incidence is increased by certain 
immunotherapies that drive T cell responses to melanoma 
[6-8]. For years, autoimmunity has been viewed as a 
side effect of robust anti-tumor immunity. New research 
now demonstrates that autoimmune melanocyte killing 
also directly maintains T cell immunity to melanoma 
[9]. The crucial role of autoimmunity in shaping anti-
tumor immunity now informs the interpretation of 
immunotherapeutic responses in the lab and in the clinic. 
In this research perspective, we explore the history linking 
melanoma and vitiligo in patients, key experiments in 
animal models that have shaped our understanding of 
this relationship, and the characteristics of memory T 
cell responses that are governed by vitiligo. Finally, we 
discuss the importance of autoimmunity for the success 
of tumor immunotherapy.
MELANOMA AND VITILIGO: 
A HISTORY OF CLINICAL 
CORRELATIONS
Melanoma and vitiligo, despite diametrically 
opposed clinical manifestations, have been empirically 
linked for over 50 years with significant implications 
for patients. Melanoma, the outgrowth of transformed 
melanocytes, has long been recognized as a particularly 
aggressive cancer, with median survival for metastatic 
disease ranging between 6-11 months [10, 11]. Surgical 
treatment has been the standard of care for nearly 150 
years [12]. One of the earliest case-based observations 
linking vitiligo and melanoma was published in 1953, 
when a patient with a ‘melanosarcoma’ developed 
depigmented lesions [13], followed by a report in 1960 
noting systemic depigmentation in a melanoma patient 
treated with radiation therapy [14]. Four years later, 
Burdick and Hawk reported regression of cutaneous and 
visceral lesions – concurrent with the development of 
vitiligo – in a metastatic melanoma patient treated with 
Vaccinia virus [15]. The following year, Smith and Sehlin 
reported the development of vitiligo in several melanoma 
patients with spontaneously regressing primary tumors 
[16]. These papers were among the first to suggest that 
tumor immunity and autoimmunity were linked. 
Beginning in the early 1970’s, studies began to 
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suggest that vitiligo portended improved prognosis for 
melanoma patients. A small study of 11 patients reported 
that survival was slightly prolonged in metastatic melanoma 
patients with vitiligo, but concluded that data supporting a 
‘direct relationship between the two conditions’ was still 
lacking [17]. Several case studies continued to comment 
on the association between vitiligo and enhanced survival 
in melanoma patients, but without statistical support [18-
20]. It wasn’t until 1983 that Nordlund and colleagues 
demonstrated significantly enhanced 5-year survival rates 
in melanoma patients with vitiligo [3]. This was followed 
by a more extensive study by Bystryn and colleagues in 
1987, which reached similar conclusions [4]. However, 
these studies included a majority of patients with Stage I 
or II disease, and data from metastatic melanoma patients 
was lacking. Recently, in a large cohort of metastatic 
melanoma patients, Quaglino and colleagues reported 
that vitiligo was an independent positive prognostic factor 
correlating with significantly enhanced 5-year survival, 
providing further support for long-reported clinical 
observations [5]. Thus vitiligo is clearly associated with 
improved immunity to melanoma in patients, though the 
mechanisms linking these phenomena remain a subject of 
active investigation.
MECHANISMS OF MELANOMA-
ASSOCIATED VITILIGO IN HUMANS
As the correlative relationship between vitiligo and 
melanoma was beginning to be described, the role of the 
immune response in melanocyte destruction was also 
under investigation. In 1971, Milton et al. argued that 
spontaneous regressions of primary melanomas implied 
active anti-tumor immunity, and suggested that associated 
vitiligo was also a manifestation of this immune response 
[17]. Supporting this argument, lymphocytic infiltrates 
were observed in melanomas of several vitiligo-affected 
patients that underwent spontaneous regression [16, 21]. 
The infiltration of lymphocytes into both melanoma and 
vitiligo lesions, as well as spontaneous regression of 
primary melanoma tumors [16], led to the hypothesis in 
1971 that depigmentation was immune-mediated [17]. Over 
the next decade, several groups postulated the ‘tempting’ 
idea that melanoma-associated vitiligo was the result of 
a cross-reactive immune response [3, 22, 23]. However, 
early studies conceded that other non-immunological 
mechanisms may be in play, and alternatives to immune 
mediated pathology were postulated [24]. Theories 
suggested that toxins from nerves, free radical scavenging, 
or byproducts from melanin manufacturing itself resulted 
in the death of melanocytes or the disabling of melanin 
production [25, 26]. 
Today, overwhelming genetic and immunologic 
evidence supports the autoimmune etiology of vitiligo in 
melanoma patients. Studies by Houghton et al. in the early 
1980’s revealed that melanoma cells express a family 
of differentiation antigens that are shared by normal 
melanocytes [1, 27]. This family of proteins includes 
tyrosinase and related proteins TRP-1 (gp75) and TRP-2 
(dopachrome tautomerase), as well as gp100, and MART-
1 (Melan-A); each of which plays a critical role in melanin 
synthesis [2]. Melanocyte differentiation antigens have 
since formed the basis for analyzing antigen-specific 
immune responses to both melanoma and melanocytes 
[28]. 
Currently, there are two major proposed mechanisms 
of vitiligo pathogenesis; one antibody based, and the other 
T cell based [29]. Autoantibodies recognizing tyrosinase, 
TRP-1, and TRP-2, have been detected in the sera of 
melanoma patients and vitiligo patients [30]. The total 
levels of antibodies directed against pigmented cells have 
also been shown to correlate with the extent of vitiligo 
in melanoma-free patients [31]. Additionally, antibodies 
found in the sera of vitiligo patients have been shown 
to lyse melanocytes and melanoma cells in vitro [32]. 
However, data supporting antibody-mediated vitiligo in 
melanoma patients have been limited. Compared with 
vitiligo patients, melanoma patients with vitiligo have 
been shown to have similar titers of antibodies to TRP-
2 [33], although they have significantly lower titers of 
antibodies directed against whole melanoma cells and 
tyrosinase [34, 35]. 
On the other hand, there is substantial evidence that 
CD8 T cells mediate melanoma-associated vitiligo. CD8 
T cells taken from lesions of vitiligo patients have been 
shown to kill melanoma cells ex vivo [36], and CD8 T 
cells from both tumors and peripheral blood of melanoma 
patients have been shown to kill normal melanocytes 
[37]. In melanoma patients with vitiligo, clonotypically 
identical T cells were found in both the tumor and 
surrounding depigmented lesions [38]. It has been shown 
that the majority of cells infiltrating these lesions are 
CD8+ T cells that recognize both normal melanocytes and 
melanoma cells [39]. Accordingly, after therapeutically 
transferring MART-1 specific CD8 T cells to a melanoma 
patient, transferred cells were found to accumulate in 
depigmented lesions that developed as a result of therapy 
[40]. CD4 T cells have also been found to infiltrate vitiligo 
lesions, although less is known about melanocyte-specific 
CD4 T cell responses [36, 41]. Two recent studies have 
identified increased levels of IL-17 in both the serum and 
tissue of vitiligo patients [42, 43], which may suggest 
CD4 T cell involvement. Therefore significant clinical 
evidence supports the theory that melanoma-associated 
vitiligo is a CD8 T cell mediated phenomenon, although 
antibodies and/or CD4 T cells may also play roles. 
LESSONS LEARNED FROM ANIMAL 
MODELS
Concurrent with these efforts to understand the 
relationship between melanoma and vitiligo in the clinic, 
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a wealth of mechanistic studies has been undertaken in 
the laboratory. Inbred C57BL/6 mice and the syngeneic, 
transplantable, B16 mouse melanoma model have 
greatly facilitated this work. Hara et al. were the first to 
report the outgrowth of white hair in black mice upon 
treatment with the TA99 monoclonal antibody to TRP-
1 [44]. Mice treated with TA99 were also protected 
against B16 melanoma, showing for the first time that 
immune responses against shared melanoma/melanocyte 
antigens could concurrently mediate tumor immunity 
and autoimmunity [44]. Since this seminal work, studies 
have turned largely to inducing CD8 T cell responses, and 
several MHC I-restricted epitopes from gp100 [45], TRP-
2 [46], tyrosinase [47], and TRP-1 [48] have since been 
employed as targets of melanoma vaccines and cellular 
therapies. T cell receptor transgenic mice with specificity 
for melanocyte antigens have also provided a valuable 
tool for understanding mechanisms driving rejection of 
established melanoma and the induction of vitiligo [49-
52]. Below we discuss the experiments in mice that have 
most contributed to our understanding of tumor immunity 
and concomitant autoimmunity. 
Primary T cell responses to melanoma and 
melanocytes
The major focus of melanoma immunotherapy 
over the past 20 years has been on breaking T cell 
tolerance to melanocyte differentiation antigens, and 
vitiligo is a common occurrence with such therapies. The 
administration of altered melanocyte antigens has been 
one strategy used to overcome tolerance. DNA vaccines 
encoding altered forms of melanocyte differentiation 
antigens, such as xenogenic gp100 [53, 54], epitope 
enriched TRP-1 [48], and randomly mutated TRP-2 
[55], have each proven effective at priming CD8 T cell 
responses, resulting in protective immunity against 
melanoma and concomitant vitiligo. Altered self-antigens 
have also been highly effective when administered in the 
context of viral vaccine vectors [56], or as heteroclitic 
peptides in combination with multifactorial adjuvants 
such as anti-CD40 and TLR agonists [57, 58]. 
Other studies have shown that altered antigen is 
not required to break tolerance to melanocyte antigens 
if sufficient inflammatory and/or costimulatory signals 
are present. For example, irradiated B16 tumor cells 
producing GM-CSF (GVAX) combined with a blocking 
monoclonal antibody to CTLA-4 breaks tolerance to 
melanocyte differentation antigens, resulting in protective 
anti-tumor immunity and vitiligo [59]. Treatment with 
monobenzone, a compound which results in melanocyte 
killing through haptenization of tyrosinase and induction 
of melanocyte autophagy [60], also leads to rejection of 
B16 melanoma tumors and the development of vitiligo 
when combined with TLR agonists [61]. Lymphopenia-
induced homeostatic T cell proliferation in the context of 
a progressive melanoma, and the absence of CD4+CD25+ 
regulatory T cells (Treg), is sufficient to break tolerance 
and induce vitiligo, likely due to the removal of both 
suppression and homeostatic cytokine sinks [62]. Thus, 
inflammatory, costimulatory, and/or cytokine stimuli may 
be sufficient to break tolerance to antigens expressed by 
melanoma cells or dying melanocytes.
Further, our own work has shown that, even in the 
absence of overt inflammatory stimuli, disruption of 
regulatory T cell-mediated suppression is sufficient to 
overcome tolerance to melanoma-expressed self-antigens. 
In B16 tumor-bearing mice, we found that depletion of 
Treg cells by treatment with anti-CD4 breaks CD8 T 
cell tolerance to TRP-2 and gp100 [63]. These tumor-
primed CD8 T cells, although unable to control growth 
of established primary B16 melanoma tumors, provide 
systemic concomitant immunity against B16 re-challenge 
[63]. Furthermore, following Treg depletion, we showed 
that surgical excision of intradermal B16 melanoma 
tumors resulted in a majority of mice developing CD8 T 
cell-mediated vitiligo [9, 63]. Interestingly, trauma to the 
skin has previously been shown to provide non-specific 
inflammation that is critical for vitiligo induction [56, 
64]. Whereas surgical tumor excision was employed in 
our model as a means for prolonging host survival, it may 
also play a role in initiating vitiligo. In fact, we typically 
observe vitiligo first at the site of surgery [9], often 
in a pattern that mimics the incision site with striking 
accuracy (Figure 1). Taken together, these studies indicate 
the existence of multiple pathways for overcoming T 
Figure 1: Vitiligo initiation at site of surgery. Mice 
bearing intradermal B16 tumors on the right flank were treated 
by anti-CD4 monoclonal antibody to deplete regulatory T cells, 
followed by surgical tumor excision, as we have previously 
described [63]. 3 weeks after surgery, vitiligo was observed 
along the surgical incision line (dotted line), and at points where 
surgical clips had pierced the skin (arrows). 
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cell tolerance to melanoma and inducing autoimmunity 
against melanocytes. 
In recent years, T cell receptor transgenic (TCR 
Tg) mouse models have provided crucial new insights 
into mechanisms driving vitiligo and effective melanoma 
immunotherapy. The pmel-1 CD8 TCR Tg mouse was the 
first such model, possessing a TCR specific for gp10025-33 in 
the context of Db [49]. The pmel T cell clone was originally 
raised by vaccination of wild-type (gp100-sufficient) mice 
with human gp100, and therefore is thought to have low to 
moderate avidity [49]. Pmel mice begin to develop mild, 
spontaneous vitiligo at ~10 weeks of age (KTB and MJT, 
unpublished observations). Moreover, adoptive transfer of 
in vitro activated pmel cells in conjunction with human 
gp100 viral vaccination, lymphodepletion, high dose IL-
2, and/or TLR stimulation induces profound vitiligo and 
regression of established melanoma in recipient mice [49, 
65-67]. 
In addition to pmel mice, a TRP-2 specific TCR 
Tg mouse with specificity for TRP-2180-188 (termed Clone 
37) was more recently generated [50]. These mice do not 
develop spontaneous vitiligo, and adoptive transfer of 
naïve Tg T cells fails to induce rejection of established 
B16 tumors [50]. The low potency of these cells may 
be a reflection of a lower avidity TCR, as Clone 37 was 
originally raised by vaccination of wild-type mice with 
murine TRP-2 [50]. A third model with specificity for 
Tyr369-377 in the context of HLA-A2.1 expresses the TCR 
from a CD8 T cell clone that was isolated following 
vaccination of albino (tyrosinase-deficient) HLA-A2.1 
transgenic mice [68, 69]. In contrast to pmel and Clone 
37 mice, Tyr369-377 TCR Tg mice develop robust vitiligo, 
with symptoms and kinetics similar to human disease, 
suggesting that they possess a higher avidity TCR [68]. 
Interestingly, high-avidity CD4 T cells are also 
capable of mediating vitiligo, which may relate to the fact 
that both melanocytes and melanoma cells can express 
MHC II molecules [70, 71]. A CD4 TCR Tg model with 
specificity for TRP-1113-127 was developed from immunized 
TRP-1-/- mice [52]. In a wild-type (TRP-1 sufficient) 
background, TCR transgene expression results in T 
cell activation and vitiligo development [72], however, 
these T cells remain naïve on a TRP-1-/- background 
[52]. Adoptive transfers of low numbers of naïve TRP-
1-specific T cells into wild-type mice results in overt 
vitiligo and potent rejection of established B16 melanoma 
when given in combination with vaccine and IL-2 [52], 
irradiation and anti-CTLA-4 [73], or in lymphopenic hosts 
[72]. Taken together, these TCR Tg models suggest that 
the development of spontaneous vitiligo in unmanipulated 
hosts may be dependent on TCR avidity for self-peptide/
MHC. These models have proven to be valuable tools for 
understanding the mechanisms behind effective melanoma 
adoptive T cell therapy.
Maintenance of memory T cell responses to 
melanoma and melanocytes
Although generating robust primary CD8 T 
cell responses to melanoma has been a subject of 
intense investigation, less emphasis has been placed 
on understanding the maintenance of T cell memory, 
particularly in the context of autoimmune disease. 
Studies have demonstrated a correlation between long-
lived protection against melanoma and depigmentation 
in experimental models [49, 63, 65, 67], although 
vitiligo-affected and unaffected mice had not been 
directly compared with regards to the quality of CD8 T 
cell memory. Furthermore, whereas the most effective 
immunotherapies against established B16 tumors clearly 
generate vitiligo [49, 73], it has remained uncertain 
whether autoimmunity confers long-term benefits for anti-
tumor immunity. Research in our laboratory demonstrated 
that mice treated by regulatory T cell depletion developed 
post-surgical CD8 T cell memory responses to TRP-2 and 
gp100 [63]. Because approximately half of these mice 
developed vitiligo, this model has enabled investigation 
of the unique features of T cell memory in hosts with 
concomitant autoimmunity.
Our recent studies reveal that CD8 memory T cells in 
vitiligo-affected hosts are potent anti-tumor effectors with 
key defining characteristics. First, vitiligo-affected hosts 
maintained gp100 and TRP-2-specific memory CD8 T cells 
at 10-fold larger frequencies, as compared with unaffected 
hosts [9]. Second, gp100-specific T cells in vitiligo-
affected mice developed an overwhelmingly effector 
memory (TEM) phenotype, in contrast to a predominantly 
central memory (TCM) phenotype in hosts without vitiligo 
[9]. In accordance with their TEM phenotype, gp100-
specific T cells in mice with vitiligo homed preferentially 
to peripheral tissue sites. Although chronically activated, 
these cells did not display phenotypic or functional signs 
of exhaustion, even more than one year after priming [9]. 
This non-exhausted phenotype was not expected, as it had 
long been speculated that exposure to self-antigen would 
drive memory T cells to exhaustion and deletion, which is 
observed in chronic viral infection models [74]. However, 
vitiligo-affected mice also exclusively maintained long-
term CD8 T cell-mediated protection against a secondary 
B16 tumor challenge, confirming the protective function 
of these cells [9]. Studies comparing memory CD8 T cell 
populations for adoptive T cell therapy had previously 
led to the hypothesis that TCM cells are more potent anti-
tumor effectors than TEM cells [67]. Our studies show that 
large populations of non-exhausted TEM cells also provide 
durable tumor protection— a unique feature of hosts with 
autoimmunity. 
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Lessons learned from melanocyte-deficient mice
Our comparison of T cell memory in vitiligo-affected 
and unaffected mice demonstrated a clear correlation 
between autoimmunity and the maintenance of robust, 
protective, T cell responses to melanoma. However, these 
studies did not address whether vitiligo directly contributed 
to T cell immunity. To specifically answer this question, 
we established the Wsh mouse model of melanocyte 
deficiency as a model of vitiligo insufficiency (Figure 2) 
[75]. Due to a mutation in the regulatory region of c-kit, 
Wsh mice are overwhelmingly melanocyte deficient, and 
appear almost completely white, with the exception of the 
retina [75, 76]. Traditionally used as a mast-cell deficient 
model, Wsh mice had not been previously employed as a 
model of vitiligo insufficiency [76]. However, these mice 
have proven to be a useful tool to investigate the role of 
melanocyte destruction in the maintenance of melanoma 
T cell responses to melanoma.
Using the Wsh model, we have recently found that 
the absence of melanocytes impairs the development of 
T cell memory to melanoma [9]. Our data show that Wsh 
mice prime gp100-specific CD8 T cells that are equivalent 
in frequency and phenotype to wild-type hosts. However, 
they are unable to develop the robust effector memory 
T cell responses that characterize hosts with vitiligo [9]. 
Instead, melanocyte-deficient mice develop small, TCM 
populations, similar to those in vitiligo-unaffected wild-
type mice [9]. Moreover, when gp100-specific CD8 T 
cells were first primed in tumor-bearing Wsh mice, and 
then adoptively transferred into melanocyte-sufficient 
mice with vitiligo, the unique TEM phenotype and homing 
function of these T cells was restored [9]. Thus, the 
fate of melanoma antigen-specific CD8 T cells was not 
pre-determined at priming, but rather was altered by 
exposure to melanocyte destruction. Additionally, robust 
populations of gp100-specific TEM cells could be rescued 
in Wsh mice by exogenous supplementation of gp100 
antigen, confirming that melanocyte antigen is required 
for the maintenance of T cell memory [9]. These studies 
establish that melanocyte antigens liberated by vitiligo 
drive the maintenance of a unique, functional, antigen-
dependent memory T cell response to melanoma [9]. The 
fact that vitiligo directly sustains immune responses to 
melanoma provides new insight into a phenomenon that 
has long been observed in the clinic and the laboratory.
Shared melanoma/melanocyte antigens vs. tumor-
specific antigens
While we have emphasized the role of autoimmunity 
in maintaining anti-tumor immunity, it is important to 
differentiate between responses directed against shared 
melanoma/melanocyte antigens and those directed against 
tumor-specific antigens. In melanoma patients, CD8 T cell 
epitopes from NY-ESO-1 [2], MAGE [2], and BRAFV600E 
[77], have been reported, and may represent natural 
tumor-specific antigens that can be targeted for protective 
anti-tumor immunity without vitiligo. Accordingly, our 
laboratory has recently shown that protective memory 
CD8 T cell responses to B16 melanoma can be generated 
in the complete absence of vitiligo if rejection antigens are 
tumor-specific [78]. In B16 tumor-bearing mice treated by 
surgery and a stimulatory mAb against the glucocorticoid-
induced TNFR family-related receptor (GITR), we found 
that protective T cell responses are preferentially directed 
against tumor-specific antigens [78]. This was evidenced 
by the fact that mice avidly rejected B16 melanoma re-
challenge, but demonstrated no cross-protection against 
JBRH melanoma. Accordingly, GITR stimulation did 
not break T cell tolerance to melanocyte differentiation 
antigens, or induce vitiligo, although it resulted in high-
avidity T cell responses against B16 tumor-expressed 
ovalbumin (OVA) as a model tumor-specific antigen [78]. 
The mechanisms whereby GITR stimulation skews T 
cell immunity to tumor-specific antigens remains under 
investigation, however these data provide evidence that 
protective CD8 memory T cell responses to melanoma 
can be generated in the absence of autoimmunity.
There is also evidence that T cell memory to tumor-
specific antigens more closely mimics classical memory 
T cell responses described in acute viral infection models 
[79]. In studies investigating CD8 T cell responses 
generated by Treg depletion and surgery in mice bearing 
B16-OVA tumors, we found that OVA-specific CD8 T 
cells develop into a small but functional memory T cell 
population, with a predominantly TCM phenotype [9]. This 
was true regardless of the vitiligo status of the host [9]. 
Generating such long-lived T cell memory against tumor-
specific antigens will be particularly important for tumors 
of essential organs, such as the liver or pancreas, where 
autoimmune responses cannot be tolerated. 
For melanoma, we propose that two major types 
Figure 2: Wsh mice as a model of vitiligo insufficiency. 
A vitiligo affected mouse (left) and a Wsh mouse (right).
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of protective memory T cell responses can be generated, 
depending on the antigen-specificity of the response 
(Figure 3). The first type, directed against shared 
melanoma/melanocyte antigens, has a more stringent set 
of requirements for T cell priming. However, if T cells 
efficiently mediate tumor rejection and induce vitiligo, 
they will develop into a unique, functional memory T 
cell response that relies on melanocyte destruction for 
its ongoing maintenance. Alternatively, a second type of 
memory, directed against tumor-specific antigens, can be 
likened to T cell responses against foreign antigens. During 
the effector phase, these T cells will target melanoma 
cells without killing healthy melanocytes. Subsequently, 
following melanoma clearance, they develop into 
classical, antigen-independent T cell memory. As both 
types of memory would be expected to provide durable 
protection against melanoma, such a model can explain 
how long-term immunity to cancer can be achieved either 
in the presence or absence of autoimmunity.
SHEDDING NEW LIGHT ON THERAPY-
INDUCED VITILIGO IN PATIENTS
Vitiligo has been more difficult to generate in 
humans than in mice, although certain immunotherapies 
clearly promote its development. In a large retrospective 
analysis of 374 metastatic melanoma patients treated with 
high-dose IL-2, a total of 84 patients (22%) developed 
treatment-related vitiligo, although in patients with 
objective clinical responses the incidence of vitiligo was 
nearly 50% [8]. Another study found that IL-2 and GM-
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CSF maintenance therapy induced vitiligo in a striking 43% 
of patients (21 out of 49), who demonstrated significantly 
enhanced survival as compared with unaffected patients 
[6]. Combination of high-dose IL-2 with CD8 adoptive 
T cell therapy (ACT) and lymphodepleting chemotherapy 
has received much attention in recent years. In a small 
study, this ACT regimen induced vitiligo in 5 out of 13 
melanoma patients, all of whom demonstrated significant 
tumor regression [7]. More recent data demonstrate that 
myeloablative regimens further improve the efficacy of 
ACT, resulting in a 70% metastatic melanoma response 
rate [80], however, the effects of such therapy on vitiligo 
development have not yet been reported. These studies 
demonstrate that high rates of vitiligo can be achieved 
with certain types of immunotherapy, and may further 
imply that therapy-induced vitiligo promotes protective 
immune responses to melanoma. Future investigation 
of melanoma/melanocyte antigen-specific T cells in 
surviving vitiligo-affected and unaffected patients should 
provide further insights into the types of T cell memory 
that mediate tumor protection in humans.
Vitiligo induction as a crucial component of 
melanoma tumor immunotherapy is by no means a new 
concept. In 1977, Lerner and Nordlund suggested that 
vitiligo should be induced in patients after resection 
of primary melanoma, and further proposed the use of 
melanocytotoxic compounds such as monobenzone 
[19, 81]. Monobenzone therapy was in fact used on a 
small cohort of late-stage melanoma patients in 1986 
and, while 11 out of 17 treated patients had complete 
responses, their vitiligo status was not reported [82]. No 
further trials have investigated the therapeutic efficacy 
of vitiligo induction in melanoma patients, however 
several groups have resurrected the hypothesis as of 
late [30, 36, 61, 83]. Recent in vitro studies by van den 
Boorn and colleagues have elucidated the mechanism by 
which monobenzone results in human melanocyte cell 
death and the downstream initiation of anti-melanocyte 
CD8 T cell responses [60]. These studies support animal 
data from the same group, where monobenzone and TLR 
agonist treatment of mice with established B16 tumors 
required CD8 T cells for efficacy [61]. Other methods of 
specifically targeting melanocytes for destruction, such 
as anti-TRP-1 mAb [84] and tert-butyl-phenol (TBP) 
[83] could be used similarly, or as an adjuvant therapy 
following surgical tumor removal. New mechanistic 
insights into the importance of vitiligo clearly support 
future investigation of vitiligo induction as a component 
of combination melanoma immunotherapies.
Finally, the development of melanocyte-unrelated 
autoimmune disease in melanoma patients warrants 
comment. In melanoma patients receiving adjuvant IFN-α 
therapy, generalized autoimmunity has been reported to 
correlate with clinical responses [85]. Similarly, following 
treatment with ipilimumab (anti-CTLA-4), over a third 
of total responding patients developed autoimmunity, 
although not limited to vitiligo [11]. While there is no 
evidence that melanocyte-unrelated autoimmune disease 
can directly promote melanoma-specific T cell responses, 
generalized autoimmunity may provide particular 
inflammatory and/or danger signals that help to overcome 
tolerance to self-antigens expressed by tumors. Specific 
attributes of tissue-specific and non-specific autoimmune 
disease that contribute to anti-tumor immunity are only 
beginning to be understood, and will require future 
investigation.
CONCLUSIONS
The development of vitiligo clearly portends 
enhanced survival in melanoma patients, and recent 
experimental data has now provided a new understanding 
of this phenomenon. Vitiligo is still reported as an ‘adverse 
event’ during clinical trial evaluation [86], however, this 
thinking is now shifting. Future studies will be necessary 
to address whether durable clinical responses in melanoma 
patients (e.g. those receiving adoptive T cell therapies) are 
supported by the concurrent progression of vitiligo. More 
broadly, given the potential efficacy of therapies that target 
shared tumor/self antigens, we propose that driving tissue-
specific autoimmune disease is both feasible and desirable 
for tumors of non-essential organs (e.g. melanoma, 
breast, prostate, and ovarian cancer). In conjunction with 
promising new cancer therapies, harnessing the supportive 
role of autoimmunity may tip the scales against tumor 
growth and in favor of lasting anti-tumor immunity.
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